BI Asset Management Fondsmaeglerselskab A S Invests $4.66 Million in Cencora, Inc. (NYSE:COR)

BI Asset Management Fondsmaeglerselskab A S acquired a new position in Cencora, Inc. (NYSE:CORFree Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,172 shares of the company’s stock, valued at approximately $4,659,000.

Several other hedge funds have also recently made changes to their positions in COR. Fisher Asset Management LLC bought a new position in shares of Cencora in the 4th quarter worth about $244,000. Trust Co. of Vermont bought a new position in shares of Cencora in the 4th quarter worth about $62,000. Wahed Invest LLC bought a new position in shares of Cencora in the 4th quarter worth about $567,000. Vanguard Group Inc. acquired a new position in Cencora during the 4th quarter valued at about $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new position in Cencora during the 4th quarter valued at about $3,307,000. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on COR shares. Citigroup boosted their target price on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird boosted their target price on Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a research note on Tuesday. SVB Leerink restated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research note on Thursday, June 27th. Finally, StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $236.10.

View Our Latest Research Report on Cencora

Insider Buying and Selling at Cencora

In other Cencora news, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the sale, the chief operating officer now owns 24,412 shares of the company’s stock, valued at approximately $5,739,017.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Gina Clark sold 1,874 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the completion of the transaction, the executive vice president now directly owns 13,284 shares in the company, valued at approximately $2,973,756.24. The disclosure for this sale can be found here. Insiders have sold 1,956,675 shares of company stock valued at $422,352,056 in the last 90 days. 15.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

COR stock traded down $0.13 during midday trading on Wednesday, reaching $222.24. 110,087 shares of the company’s stock traded hands, compared to its average volume of 1,380,808. The company has a 50-day moving average price of $226.87 and a two-hundred day moving average price of $229.23. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The firm has a market capitalization of $44.33 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45.

Cencora (NYSE:CORGet Free Report) last issued its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The business had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same quarter in the previous year, the firm posted $3.50 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.92%. Cencora’s payout ratio is 22.32%.

Cencora Company Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Read More

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.